Skip to content

Breathing Control in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Breathing Control in Patients With Chronic Obstructive Pulmonary Disease (COPD) Intervention With Device-guided Breathing Control in COPD

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01512043
Enrollment
150
Registered
2012-01-19
Start date
2011-07-31
Completion date
2013-09-30
Last updated
2014-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Keywords

Breathlessness, Symptoms, Quality of life

Brief summary

There is a demand for explorative and comparative studies on various non-pharmaceutical efforts in treating and helping chronic obstructive pulmonary disease patients. This study has been developed in light of this need. The main purpose of the project is to test whether a device guided breathing control system can decreasing the feeling of breathlessness in patients with moderate stage and severe stage of COPD. In addition the study could shed light on whether a reduced feeling of breathlessness can lead to improved physical function, and less experience of other symptoms (I.e., depression, anxiety, sleeping difficulties, fatigue, pain) and provide a better quality of life for patients with COPD.

Interventions

Practice of device guided breathing control twice a day for four weeks.

Sponsors

University of Oslo
CollaboratorOTHER
Norwegian Foundation for Health and Rehabilitation
CollaboratorOTHER
University of Bergen
CollaboratorOTHER
Lovisenberg Diakonale Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Dyspnoea symptoms in daily life * Spirometry values showing a COPD moderate stage II (FEV1/FVC\<70%, FEV1\<80%) and severity grade at a severe stage III (FEV1/FVC\<70%, FEV1\<50% and FEV1 = 30% of a predicted) * Be able to read, write and speak Norwegian * Be at a stable phase of the disease

Exclusion criteria

* Changes in pulmonary medication during the last 4 weeks * Diagnosis of cancer * Presently attending a pulmonary rehabilitation course or other similar COPD education courses (due to the fact that these courses often have instructions on breathing control), or having attended similar courses during the last six months * Ongoing exacerbation * Attending other competitive studies * Diagnosis of neuromuscular disease * Diagnosis of dementia * Attending help from a pulmonary physiotherapist

Design outcomes

Primary

MeasureTime frameDescription
Breathlessness4 monthsQuestionnaires

Secondary

MeasureTime frameDescription
Pulmonary functional tests4 months
Anxiety4 monthsQuestionnaires
Fatigue4 monthsQuestionnaire
Sleeping difficulties4 monthsQuestionnaires
Depression4 monthsQuestionnaires
6. Min walk test4 months
Arterial blood gas measures4 months
Quality of life4 monthsQuestionnaire
Pain4 monthsQuestionnaire

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026